Thyroid, Hormones & Cardiovascular Risk

Introduction: Hormones as Cardiovascular Regulators

The cardiovascular system does not operate independently of the endocrine system. Every major hormone — thyroid hormones, estrogen, testosterone, cortisol, insulin, and aldosterone — exerts direct and significant effects on the heart, blood vessels, lipid metabolism, and inflammatory tone. Hormonal imbalances are therefore not merely reproductive or metabolic concerns; they are cardiovascular risk factors of the first order.

Yet conventional cardiovascular risk assessment rarely includes comprehensive hormonal evaluation. Lipid panels, blood pressure measurements, and glucose testing dominate the standard workup — while thyroid dysfunction, sex hormone imbalances, and HPA axis dysregulation go undetected and unaddressed. A root-cause approach to cardiovascular health demands that we look at the full hormonal landscape and understand how each imbalance contributes to cardiac and vascular disease.

Thyroid Hormones & the Heart

The thyroid gland produces thyroxine (T4) and triiodothyronine (T3) — hormones that regulate the metabolic rate of virtually every cell in the body, including cardiomyocytes. The heart is exquisitely sensitive to thyroid status, and both hypothyroidism and hyperthyroidism carry significant cardiovascular consequences.

Hypothyroidism & Cardiovascular Risk

Even subclinical hypothyroidism (elevated TSH with normal T4) is associated with a substantially increased cardiovascular risk profile:

• Dyslipidemia: Hypothyroidism reduces LDL receptor expression and lipoprotein lipase activity, elevating total cholesterol, LDL, and triglycerides. Thyroid hormone replacement consistently improves lipid profiles — in some cases eliminating the need for statins
• Hypertension: Reduced thyroid hormone impairs endothelial nitric oxide production and increases peripheral vascular resistance, raising diastolic blood pressure
• Reduced cardiac output: T3 directly stimulates cardiac contractility and heart rate; hypothyroidism reduces both, impairing cardiac output and exercise tolerance
• Atherosclerosis acceleration: Hypothyroidism promotes endothelial dysfunction, elevated homocysteine, increased CRP, and impaired reverse cholesterol transport — all pro-atherogenic
• Pericardial effusion: Severe hypothyroidism can cause fluid accumulation around the heart
• Heart failure: Thyroid hormone is required for normal myocardial gene expression; deficiency impairs cardiac remodeling and contractile protein synthesis

A meta-analysis of 55,287 individuals found that subclinical hypothyroidism was associated with a 20% increased risk of coronary heart disease events and a 29% increased risk of coronary heart disease mortality — effects most pronounced in those with TSH >10 mIU/L.

Hyperthyroidism & Cardiovascular Risk

Excess thyroid hormone creates a hyperadrenergic cardiovascular state:

• Atrial fibrillation: The most common cardiac complication of hyperthyroidism; occurs in 10–25% of hyperthyroid patients and is the presenting symptom in many older adults
• Tachycardia and palpitations: Elevated T3 increases heart rate and cardiac output, increasing myocardial oxygen demand
• Hypertension: Elevated systolic pressure from increased cardiac output; widened pulse pressure
• Heart failure: High-output heart failure from sustained tachycardia and increased cardiac workload
• Increased thromboembolism risk: AF-associated stroke risk is particularly elevated in hyperthyroid patients

The T3/T4 Conversion Problem

Many individuals have normal TSH and T4 but impaired conversion of T4 to the active T3 form — a pattern missed by standard thyroid testing. Low free T3 with normal TSH creates a tissue-level hypothyroid state with cardiovascular consequences identical to overt hypothyroidism. Root causes of impaired T4-to-T3 conversion include selenium deficiency, chronic inflammation, elevated cortisol, gut dysbiosis, and exposure to environmental toxins (particularly bromide, fluoride, and chlorine, which compete with iodine).

Estrogen & Cardiovascular Health

Estrogen is a potent cardiovascular protector in premenopausal women — a key reason why women's cardiovascular disease risk lags men's by approximately a decade. Estrogen's cardiovascular effects include:

• Upregulation of eNOS and nitric oxide production, promoting vasodilation
• Antioxidant effects on LDL, reducing oxidized LDL formation
• Favorable lipid effects: raises HDL, lowers LDL and Lp(a)
• Anti-inflammatory effects on vascular endothelium
• Inhibition of vascular smooth muscle cell proliferation
• Improved insulin sensitivity

Menopause & Cardiovascular Risk Acceleration

The precipitous decline in estrogen at menopause removes these protective effects and triggers a rapid acceleration of cardiovascular risk. Within 5–10 years of menopause, women's cardiovascular disease rates approach and eventually exceed those of age-matched men. Menopausal cardiovascular changes include:

• Rapid LDL increase (average +10–15 mg/dL) and HDL decrease
• Increased visceral adiposity and insulin resistance
• Endothelial dysfunction and arterial stiffness
• Increased inflammatory markers (CRP, IL-6)
• Accelerated atherosclerosis progression

Hormone Replacement Therapy: The Timing Hypothesis

The cardiovascular effects of hormone replacement therapy (HRT) depend critically on timing. The "timing hypothesis" — supported by the KEEPS and ELITE trials — proposes that HRT initiated within 10 years of menopause (or before age 60) is cardioprotective, while initiation in older women with established atherosclerosis may be harmful. Transdermal estradiol (avoiding first-pass hepatic metabolism) combined with micronized progesterone appears to have the most favorable cardiovascular risk profile.

Estrogen Dominance & Cardiovascular Risk

In both men and women, excess estrogen relative to progesterone (estrogen dominance) promotes:

• Increased clotting factors and thrombosis risk
• Elevated triglycerides
• Fluid retention and hypertension
• Increased inflammatory tone

Root causes include excess body fat (adipose tissue converts androgens to estrogen via aromatase), impaired hepatic estrogen metabolism, gut dysbiosis (the "estrobolome" — gut bacteria that deconjugate estrogens for reabsorption), and xenoestrogen exposure from plastics and pesticides.

Testosterone & Cardiovascular Health

Testosterone's cardiovascular role is more nuanced than its reputation suggests. Physiological testosterone levels are cardioprotective; deficiency is a significant cardiovascular risk factor in both men and women.

Low Testosterone & Cardiovascular Risk in Men

Hypogonadism (low testosterone) is associated with:

• Increased visceral adiposity and insulin resistance
• Elevated LDL, triglycerides, and reduced HDL
• Endothelial dysfunction and reduced nitric oxide production
• Increased inflammatory markers (CRP, IL-6)
• Increased arterial stiffness and carotid intima-media thickness
• Higher rates of metabolic syndrome, type 2 diabetes, and cardiovascular events

Large observational studies consistently find that men with low testosterone have higher cardiovascular mortality. Testosterone replacement therapy (TRT) in hypogonadal men improves insulin sensitivity, reduces visceral fat, improves lipid profiles, and reduces inflammatory markers — though long-term cardiovascular outcome data from randomized trials (including the TRAVERSE trial) show a neutral to modestly increased risk of atrial fibrillation and pulmonary embolism, requiring individualized risk-benefit assessment.

Testosterone in Women

Women produce testosterone in the ovaries and adrenal glands; levels decline with age and menopause. Low testosterone in women is associated with reduced lean muscle mass, increased visceral adiposity, impaired insulin sensitivity, and reduced libido — all cardiovascular risk factors. Conversely, excess testosterone (as in polycystic ovary syndrome, PCOS) is associated with insulin resistance, dyslipidemia, hypertension, and significantly elevated cardiovascular risk.

Cortisol & the HPA Axis: Stress Hormones and the Heart

Chronic HPA axis activation and cortisol excess represent one of the most underappreciated cardiovascular risk factors in modern medicine. Cortisol's cardiovascular effects include:

• Hypertension: Cortisol activates mineralocorticoid receptors, promoting sodium retention and volume expansion; it also sensitizes blood vessels to catecholamines
• Dyslipidemia: Elevates LDL, triglycerides, and promotes visceral fat accumulation
• Insulin resistance: Cortisol antagonizes insulin signaling in muscle and liver, promoting hyperglycemia and metabolic syndrome
• Endothelial dysfunction: Reduces eNOS activity and nitric oxide production
• Pro-inflammatory: Paradoxically, chronic cortisol elevation promotes systemic inflammation through glucocorticoid receptor desensitization
• Magnesium depletion: Increases urinary magnesium excretion, compounding cardiovascular risk
• Platelet activation: Catecholamines released during stress increase platelet aggregation and thrombosis risk

Cushing's syndrome — pathological cortisol excess — is associated with a 4-fold increase in cardiovascular mortality, providing a clinical model for the cardiovascular consequences of chronic cortisol elevation at more modest levels.

Insulin & Aldosterone: The Metabolic-Cardiovascular Hormones

Insulin Resistance

Hyperinsulinemia and insulin resistance are central to the metabolic cardiovascular syndrome. Excess insulin directly promotes:

• Vascular smooth muscle cell proliferation and arterial wall thickening
• Sodium retention and hypertension via renal tubular effects
• Sympathetic nervous system activation
• Endothelial dysfunction through reduced NO production
• Dyslipidemia: elevated VLDL, triglycerides, and small dense LDL; reduced HDL

Aldosterone

Aldosterone — the primary mineralocorticoid — regulates sodium and potassium balance but also exerts direct cardiovascular effects when chronically elevated. Primary aldosteronism (excess aldosterone from adrenal adenoma or hyperplasia) causes hypertension, hypokalemia, and significantly elevated cardiovascular risk — including a 4-fold higher rate of atrial fibrillation and increased stroke risk compared to essential hypertension of equivalent blood pressure. Aldosterone promotes cardiac fibrosis, endothelial dysfunction, and vascular inflammation independently of its blood pressure effects.

Comprehensive Hormonal Cardiovascular Assessment

A root-cause cardiovascular workup should include hormonal evaluation beyond standard testing:

• Thyroid panel: TSH, free T4, free T3, reverse T3, thyroid antibodies (TPO, TgAb)
• Sex hormones: Total and free testosterone, estradiol, progesterone, DHEA-S, SHBG
• Adrenal function: 4-point salivary cortisol (morning, noon, afternoon, evening) for HPA axis rhythm assessment; DHEA-S
• Metabolic hormones: Fasting insulin, HOMA-IR, HbA1c, fasting glucose
• Aldosterone/renin ratio: Screen for primary aldosteronism in resistant hypertension

Root-Cause Interventions for Hormonal Cardiovascular Risk

• Thyroid optimization: Selenium (200 mcg/day) for T4-to-T3 conversion; iodine sufficiency; toxin reduction; treat autoimmune thyroiditis with LDN or dietary interventions; consider T3-containing thyroid replacement when conversion is impaired
• Estrogen balance: DIM (diindolylmethane) and calcium-d-glucarate for estrogen metabolism; cruciferous vegetables; reduce xenoestrogen exposure; support the estrobolome with probiotics and fiber
• Testosterone support: Resistance training, zinc, vitamin D, ashwagandha, and sleep optimization for natural testosterone support; TRT with appropriate monitoring when clinically indicated
• Cortisol regulation: Adaptogenic herbs (ashwagandha, rhodiola, holy basil); HRV biofeedback; sleep optimization; phosphatidylserine (400–800 mg/day) for HPA axis downregulation
• Insulin sensitivity: Low-glycemic nutrition, intermittent fasting, resistance training, berberine, magnesium, and chromium

Conclusion: Hormonal Balance as Cardiovascular Medicine

The hormonal system is not separate from the cardiovascular system — it is one of its primary regulators. Thyroid dysfunction, sex hormone imbalances, HPA axis dysregulation, and insulin resistance are not peripheral endocrine concerns; they are mechanistically central drivers of hypertension, dyslipidemia, atherosclerosis, arrhythmia, and heart failure.

A root-cause approach to cardiovascular health must therefore include comprehensive hormonal assessment and targeted rebalancing. Treating the lipid panel while ignoring the hypothyroidism that caused it, or managing blood pressure while overlooking the cortisol excess driving it, is symptom management — not root-cause medicine. True cardiovascular prevention requires seeing the whole hormonal picture and intervening at its source.